| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathy, Hypertrophic | 147 | 2025 | 750 | 27.200 |
Why?
|
| Ventricular Outflow Obstruction | 19 | 2025 | 114 | 6.010 |
Why?
|
| Atrial Fibrillation | 22 | 2024 | 798 | 5.650 |
Why?
|
| Death, Sudden, Cardiac | 50 | 2024 | 354 | 5.490 |
Why?
|
| Defibrillators, Implantable | 30 | 2024 | 258 | 5.300 |
Why?
|
| Magnetic Resonance Imaging, Cine | 20 | 2024 | 108 | 4.230 |
Why?
|
| Heart Failure | 26 | 2024 | 867 | 4.070 |
Why?
|
| Ventricular Septum | 8 | 2022 | 30 | 2.700 |
Why?
|
| Tachycardia, Ventricular | 10 | 2023 | 118 | 2.580 |
Why?
|
| Myocardium | 14 | 2024 | 262 | 2.280 |
Why?
|
| Humans | 170 | 2025 | 59512 | 2.250 |
Why?
|
| Cardiac Surgical Procedures | 15 | 2023 | 249 | 2.170 |
Why?
|
| Contrast Media | 16 | 2024 | 413 | 2.150 |
Why?
|
| Heart Transplantation | 10 | 2024 | 159 | 2.030 |
Why?
|
| Gadolinium | 12 | 2024 | 102 | 2.020 |
Why?
|
| Electrocardiography | 12 | 2024 | 524 | 1.940 |
Why?
|
| Risk Assessment | 20 | 2024 | 1915 | 1.940 |
Why?
|
| Anti-Arrhythmia Agents | 7 | 2025 | 93 | 1.830 |
Why?
|
| Middle Aged | 67 | 2025 | 16278 | 1.820 |
Why?
|
| Heart Septum | 10 | 2022 | 55 | 1.800 |
Why?
|
| Heart Aneurysm | 6 | 2021 | 23 | 1.700 |
Why?
|
| Male | 81 | 2025 | 27582 | 1.700 |
Why?
|
| Ablation Techniques | 5 | 2020 | 22 | 1.600 |
Why?
|
| Adult | 62 | 2025 | 15776 | 1.590 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2021 | 160 | 1.570 |
Why?
|
| Cardiomyopathies | 3 | 2022 | 120 | 1.550 |
Why?
|
| Treatment Outcome | 30 | 2025 | 5180 | 1.550 |
Why?
|
| Amyloidosis | 3 | 2022 | 59 | 1.550 |
Why?
|
| Echocardiography | 13 | 2021 | 459 | 1.520 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2023 | 2040 | 1.500 |
Why?
|
| Ventricular Fibrillation | 8 | 2023 | 99 | 1.490 |
Why?
|
| Risk Factors | 37 | 2024 | 5014 | 1.470 |
Why?
|
| Retrospective Studies | 30 | 2025 | 6013 | 1.420 |
Why?
|
| Female | 69 | 2025 | 30914 | 1.380 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 5 | 2023 | 28 | 1.300 |
Why?
|
| Aged | 38 | 2025 | 13358 | 1.240 |
Why?
|
| Electric Countershock | 8 | 2024 | 98 | 1.230 |
Why?
|
| Heart Ventricles | 10 | 2022 | 251 | 1.180 |
Why?
|
| Primary Prevention | 4 | 2021 | 137 | 1.140 |
Why?
|
| Disopyramide | 2 | 2025 | 10 | 1.140 |
Why?
|
| Young Adult | 28 | 2024 | 4326 | 1.130 |
Why?
|
| Follow-Up Studies | 15 | 2025 | 2329 | 1.090 |
Why?
|
| Vascular Diseases | 2 | 2024 | 71 | 1.060 |
Why?
|
| Ventricular Function, Left | 12 | 2025 | 263 | 1.050 |
Why?
|
| Stroke | 4 | 2024 | 1138 | 1.030 |
Why?
|
| Amyloid Neuropathies, Familial | 2 | 2022 | 17 | 1.010 |
Why?
|
| Mitral Valve | 5 | 2023 | 104 | 1.000 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2025 | 21 | 0.960 |
Why?
|
| Catheter Ablation | 3 | 2023 | 140 | 0.950 |
Why?
|
| Survival Rate | 11 | 2024 | 790 | 0.940 |
Why?
|
| Papillary Muscles | 2 | 2015 | 14 | 0.920 |
Why?
|
| Athletes | 7 | 2024 | 97 | 0.920 |
Why?
|
| Quality of Life | 7 | 2024 | 1118 | 0.920 |
Why?
|
| Precision Medicine | 2 | 2022 | 104 | 0.920 |
Why?
|
| Predictive Value of Tests | 18 | 2024 | 1029 | 0.880 |
Why?
|
| Atrial Appendage | 1 | 2024 | 28 | 0.880 |
Why?
|
| Phenotype | 15 | 2024 | 1150 | 0.860 |
Why?
|
| Prognosis | 21 | 2024 | 1572 | 0.830 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2020 | 15 | 0.800 |
Why?
|
| Return to Sport | 2 | 2021 | 10 | 0.780 |
Why?
|
| Cardiovascular System | 1 | 2022 | 41 | 0.780 |
Why?
|
| Stroke Volume | 8 | 2025 | 321 | 0.760 |
Why?
|
| Cardiovascular Agents | 1 | 2022 | 101 | 0.730 |
Why?
|
| Adolescent | 19 | 2024 | 5922 | 0.710 |
Why?
|
| Hemodynamics | 3 | 2017 | 235 | 0.690 |
Why?
|
| Disease Progression | 8 | 2024 | 1048 | 0.660 |
Why?
|
| Longevity | 2 | 2017 | 111 | 0.660 |
Why?
|
| Cardiotonic Agents | 3 | 2018 | 48 | 0.650 |
Why?
|
| Aortic Valve | 2 | 2020 | 170 | 0.650 |
Why?
|
| Sports | 4 | 2024 | 92 | 0.650 |
Why?
|
| Hypertrophy, Left Ventricular | 7 | 2023 | 122 | 0.640 |
Why?
|
| Time Factors | 13 | 2025 | 3583 | 0.640 |
Why?
|
| Exercise Test | 3 | 2018 | 234 | 0.640 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 52 | 0.640 |
Why?
|
| Referral and Consultation | 2 | 2019 | 410 | 0.630 |
Why?
|
| Heart Failure, Systolic | 2 | 2021 | 16 | 0.620 |
Why?
|
| Child | 16 | 2024 | 4313 | 0.610 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2020 | 98 | 0.600 |
Why?
|
| Waiting Lists | 1 | 2018 | 48 | 0.590 |
Why?
|
| Echocardiography, Stress | 1 | 2017 | 13 | 0.590 |
Why?
|
| Kidney Diseases | 1 | 2019 | 159 | 0.580 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 155 | 0.580 |
Why?
|
| Exercise Tolerance | 1 | 2017 | 71 | 0.570 |
Why?
|
| Critical Pathways | 1 | 2017 | 32 | 0.570 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 172 | 0.570 |
Why?
|
| Cicatrix | 7 | 2024 | 58 | 0.550 |
Why?
|
| Guideline Adherence | 1 | 2019 | 296 | 0.550 |
Why?
|
| Heart | 6 | 2024 | 276 | 0.550 |
Why?
|
| Obesity | 1 | 2025 | 1186 | 0.550 |
Why?
|
| Systole | 5 | 2021 | 109 | 0.530 |
Why?
|
| Fibrosis | 8 | 2024 | 151 | 0.520 |
Why?
|
| Cohort Studies | 10 | 2024 | 2443 | 0.510 |
Why?
|
| Mutation | 10 | 2024 | 2445 | 0.510 |
Why?
|
| Heart-Assist Devices | 1 | 2018 | 126 | 0.510 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2015 | 19 | 0.500 |
Why?
|
| Magnetic Resonance Spectroscopy | 5 | 2022 | 293 | 0.500 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 705 | 0.480 |
Why?
|
| Angina, Stable | 1 | 2014 | 10 | 0.480 |
Why?
|
| Aged, 80 and over | 14 | 2020 | 5100 | 0.470 |
Why?
|
| Disease Management | 6 | 2020 | 220 | 0.470 |
Why?
|
| Coronary Stenosis | 1 | 2014 | 31 | 0.460 |
Why?
|
| Cardiac Imaging Techniques | 3 | 2022 | 16 | 0.450 |
Why?
|
| Coronary Angiography | 1 | 2014 | 172 | 0.450 |
Why?
|
| Coronary Vessels | 1 | 2014 | 109 | 0.440 |
Why?
|
| Incidence | 6 | 2022 | 1242 | 0.440 |
Why?
|
| Heart Failure, Diastolic | 1 | 2013 | 9 | 0.440 |
Why?
|
| Electrodes | 1 | 2013 | 36 | 0.420 |
Why?
|
| Scalp | 1 | 2013 | 29 | 0.410 |
Why?
|
| Ambulatory Care | 1 | 2014 | 300 | 0.390 |
Why?
|
| Anticoagulants | 4 | 2024 | 485 | 0.390 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 150 | 0.390 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 427 | 0.370 |
Why?
|
| Benzylamines | 2 | 2022 | 29 | 0.370 |
Why?
|
| Recovery of Function | 4 | 2019 | 261 | 0.350 |
Why?
|
| Heart Arrest | 2 | 2022 | 159 | 0.350 |
Why?
|
| Hypertension, Pulmonary | 2 | 2022 | 78 | 0.320 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1454 | 0.320 |
Why?
|
| Infant, Newborn | 1 | 2013 | 1306 | 0.310 |
Why?
|
| Risk Management | 1 | 2008 | 39 | 0.300 |
Why?
|
| Medical Staff, Hospital | 1 | 2008 | 59 | 0.300 |
Why?
|
| Massachusetts | 3 | 2020 | 2096 | 0.300 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2019 | 94 | 0.300 |
Why?
|
| Adipose Tissue | 1 | 2010 | 282 | 0.300 |
Why?
|
| Nursing Staff, Hospital | 1 | 2008 | 72 | 0.290 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 1463 | 0.280 |
Why?
|
| Genotype | 4 | 2024 | 639 | 0.280 |
Why?
|
| Cardiac Catheterization | 3 | 2024 | 246 | 0.280 |
Why?
|
| Comorbidity | 2 | 2021 | 1090 | 0.280 |
Why?
|
| Mass Screening | 1 | 2012 | 649 | 0.270 |
Why?
|
| Medical Errors | 1 | 2008 | 193 | 0.270 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2024 | 167 | 0.260 |
Why?
|
| Cardiology | 2 | 2019 | 164 | 0.250 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 821 | 0.240 |
Why?
|
| Gadolinium DTPA | 4 | 2018 | 85 | 0.240 |
Why?
|
| Septal Occluder Device | 1 | 2024 | 11 | 0.230 |
Why?
|
| Age Factors | 5 | 2024 | 1516 | 0.230 |
Why?
|
| Uracil | 2 | 2022 | 30 | 0.230 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 672 | 0.230 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2022 | 85 | 0.230 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1226 | 0.220 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 141 | 0.220 |
Why?
|
| Propensity Score | 1 | 2024 | 133 | 0.220 |
Why?
|
| Death, Sudden | 1 | 2023 | 27 | 0.220 |
Why?
|
| Patient Selection | 5 | 2018 | 447 | 0.210 |
Why?
|
| Soccer | 1 | 2022 | 13 | 0.210 |
Why?
|
| Prealbumin | 1 | 2022 | 20 | 0.210 |
Why?
|
| Interatrial Block | 1 | 2022 | 2 | 0.210 |
Why?
|
| Heart Valve Diseases | 1 | 2023 | 88 | 0.200 |
Why?
|
| United States | 9 | 2024 | 7530 | 0.200 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 904 | 0.200 |
Why?
|
| Boston | 2 | 2020 | 331 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2024 | 673 | 0.200 |
Why?
|
| Consensus | 2 | 2021 | 195 | 0.190 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2021 | 18 | 0.190 |
Why?
|
| Echocardiography, Doppler | 3 | 2017 | 131 | 0.190 |
Why?
|
| Embolization, Therapeutic | 2 | 2015 | 306 | 0.190 |
Why?
|
| Ontario | 1 | 2021 | 44 | 0.190 |
Why?
|
| Prospective Studies | 8 | 2024 | 3102 | 0.190 |
Why?
|
| Writing | 1 | 2021 | 43 | 0.190 |
Why?
|
| One Health | 1 | 2021 | 2 | 0.190 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 119 | 0.180 |
Why?
|
| Prevalence | 6 | 2023 | 1286 | 0.180 |
Why?
|
| Heart Conduction System | 1 | 2021 | 49 | 0.180 |
Why?
|
| Sarcomeres | 4 | 2022 | 51 | 0.180 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2021 | 75 | 0.180 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2020 | 7 | 0.180 |
Why?
|
| Image Enhancement | 3 | 2021 | 190 | 0.180 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2019 | 270 | 0.170 |
Why?
|
| Judgment | 1 | 2020 | 30 | 0.170 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 2 | 2017 | 14 | 0.170 |
Why?
|
| Reference Standards | 1 | 2020 | 61 | 0.170 |
Why?
|
| Syncope | 1 | 2020 | 42 | 0.170 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 56 | 0.170 |
Why?
|
| Proteome | 1 | 2021 | 137 | 0.170 |
Why?
|
| Diseases in Twins | 1 | 2020 | 54 | 0.170 |
Why?
|
| Constriction, Pathologic | 1 | 2020 | 104 | 0.170 |
Why?
|
| Asymptomatic Diseases | 2 | 2017 | 44 | 0.170 |
Why?
|
| Genomics | 1 | 2022 | 314 | 0.170 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 139 | 0.170 |
Why?
|
| Ethanol | 2 | 2020 | 307 | 0.170 |
Why?
|
| Safety | 1 | 2020 | 141 | 0.170 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 149 | 0.160 |
Why?
|
| Sex Factors | 2 | 2019 | 962 | 0.160 |
Why?
|
| Patients | 1 | 2020 | 103 | 0.160 |
Why?
|
| Europe | 4 | 2024 | 183 | 0.160 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 95 | 0.160 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2018 | 33 | 0.150 |
Why?
|
| Myocardial Reperfusion | 1 | 2018 | 24 | 0.150 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2017 | 24 | 0.150 |
Why?
|
| Biomarkers | 2 | 2021 | 1198 | 0.150 |
Why?
|
| Health Status | 2 | 2018 | 449 | 0.150 |
Why?
|
| Sotalol | 1 | 2017 | 7 | 0.150 |
Why?
|
| Tertiary Healthcare | 1 | 2017 | 13 | 0.150 |
Why?
|
| Fabry Disease | 1 | 2017 | 8 | 0.150 |
Why?
|
| Amiodarone | 1 | 2017 | 21 | 0.140 |
Why?
|
| Hospitalization | 1 | 2025 | 1287 | 0.140 |
Why?
|
| Hypertension | 1 | 2023 | 600 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2018 | 155 | 0.140 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2017 | 39 | 0.140 |
Why?
|
| Cardiac Myosins | 1 | 2017 | 22 | 0.140 |
Why?
|
| Myosin Heavy Chains | 1 | 2017 | 40 | 0.140 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 203 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2018 | 146 | 0.130 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 90 | 0.130 |
Why?
|
| Tertiary Care Centers | 3 | 2024 | 102 | 0.130 |
Why?
|
| Reproducibility of Results | 5 | 2022 | 1554 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2024 | 142 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2017 | 553 | 0.130 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 66 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2019 | 737 | 0.130 |
Why?
|
| Recurrence | 1 | 2017 | 577 | 0.130 |
Why?
|
| Carrier Proteins | 2 | 2017 | 709 | 0.120 |
Why?
|
| Physicians | 1 | 2020 | 437 | 0.120 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 81 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2017 | 521 | 0.120 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2014 | 4 | 0.120 |
Why?
|
| Inflammation | 1 | 2021 | 1104 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 332 | 0.110 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2013 | 35 | 0.110 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 21 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 315 | 0.110 |
Why?
|
| Global Health | 3 | 2021 | 164 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2015 | 330 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2475 | 0.100 |
Why?
|
| False Negative Reactions | 1 | 2012 | 40 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 860 | 0.100 |
Why?
|
| Coronary Artery Bypass | 2 | 2023 | 274 | 0.090 |
Why?
|
| Genetic Testing | 2 | 2024 | 132 | 0.090 |
Why?
|
| Biopsy | 1 | 2010 | 375 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1056 | 0.080 |
Why?
|
| Hospitals, Voluntary | 1 | 2008 | 1 | 0.080 |
Why?
|
| Medical Informatics Applications | 1 | 2008 | 15 | 0.080 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 2 | 2017 | 23 | 0.070 |
Why?
|
| Pedigree | 2 | 2017 | 190 | 0.060 |
Why?
|
| Internet | 1 | 2008 | 460 | 0.060 |
Why?
|
| Mortality | 2 | 2015 | 161 | 0.060 |
Why?
|
| Registries | 2 | 2019 | 804 | 0.060 |
Why?
|
| Bundle-Branch Block | 1 | 2024 | 14 | 0.060 |
Why?
|
| Iatrogenic Disease | 1 | 2024 | 57 | 0.060 |
Why?
|
| DNA Mutational Analysis | 2 | 2014 | 194 | 0.050 |
Why?
|
| Universities | 1 | 2024 | 151 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2023 | 125 | 0.050 |
Why?
|
| Vascular Remodeling | 1 | 2022 | 23 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2024 | 773 | 0.050 |
Why?
|
| Darkness | 1 | 2021 | 22 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 178 | 0.050 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2021 | 12 | 0.050 |
Why?
|
| Cell Communication | 1 | 2022 | 127 | 0.050 |
Why?
|
| Workload | 1 | 2022 | 121 | 0.050 |
Why?
|
| Endophenotypes | 1 | 2021 | 8 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2022 | 131 | 0.050 |
Why?
|
| Multi-Institutional Systems | 1 | 2020 | 5 | 0.050 |
Why?
|
| Protein Interaction Maps | 1 | 2021 | 33 | 0.050 |
Why?
|
| Publication Bias | 1 | 2020 | 21 | 0.050 |
Why?
|
| Ligands | 1 | 2022 | 421 | 0.040 |
Why?
|
| Dilatation | 1 | 2020 | 29 | 0.040 |
Why?
|
| Subcutaneous Tissue | 1 | 2020 | 14 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 140 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 108 | 0.040 |
Why?
|
| Autopsy | 1 | 2020 | 46 | 0.040 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 9 | 0.040 |
Why?
|
| Twins, Monozygotic | 1 | 2020 | 69 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2019 | 34 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 168 | 0.040 |
Why?
|
| Community Health Services | 1 | 2020 | 128 | 0.040 |
Why?
|
| Models, Animal | 1 | 2019 | 221 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 317 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2020 | 258 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2019 | 154 | 0.040 |
Why?
|
| American Heart Association | 1 | 2019 | 128 | 0.040 |
Why?
|
| New Jersey | 1 | 2018 | 26 | 0.040 |
Why?
|
| Australia | 1 | 2018 | 94 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 331 | 0.040 |
Why?
|
| alpha-Galactosidase | 1 | 2017 | 8 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2018 | 70 | 0.040 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2017 | 15 | 0.040 |
Why?
|
| Ventricular Function | 1 | 2017 | 21 | 0.040 |
Why?
|
| Swine | 1 | 2018 | 348 | 0.040 |
Why?
|
| Dyspnea | 1 | 2018 | 108 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 2017 | 44 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2018 | 137 | 0.030 |
Why?
|
| Physical Exertion | 1 | 2017 | 78 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 19654 | 0.030 |
Why?
|
| Action Potentials | 1 | 2017 | 103 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2023 | 1136 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 207 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 147 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 118 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2017 | 80 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 180 | 0.030 |
Why?
|
| Rats | 1 | 2019 | 1914 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2018 | 364 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2016 | 65 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 191 | 0.030 |
Why?
|
| Heart Rate | 1 | 2017 | 306 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2015 | 71 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2016 | 206 | 0.030 |
Why?
|
| Mental Health | 1 | 2018 | 349 | 0.030 |
Why?
|
| Anxiety | 1 | 2018 | 396 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 199 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2015 | 70 | 0.030 |
Why?
|
| Heart Atria | 1 | 2015 | 138 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 132 | 0.030 |
Why?
|
| Myocardial Contraction | 1 | 2013 | 83 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 841 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 180 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 576 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 401 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2013 | 244 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 925 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 422 | 0.030 |
Why?
|
| Minnesota | 1 | 2012 | 38 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2017 | 1836 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 387 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2018 | 738 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2021 | 2888 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2016 | 840 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 637 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 10273 | 0.020 |
Why?
|